Optimi Health Completes MDMA Export for PTSD Treatment Under Australia's Authorised Prescriber Scheme

Rhea-AI Summary

Optimi Health (OTCQX: OPTHF) completed its first 2026 export of MDMA capsules to Australia under the Authorised Prescriber Scheme on February 9, 2026. The shipment comprised 1,000 MDMA capsules (60 mg), sufficient for over 300 authorised PTSD treatment sessions, following required Australian import and Health Canada export permits.

Patient-reported outcomes are being collected by the Australian National University to contribute to real-world evidence, and an Australian licensed pharmacy partner serves as importer of record and national distributor.

Positive

• Completed export of 1,000 MDMA capsules (60 mg) to Australia
• Supply for 300+ authorised PTSD treatment sessions
• Patient-reported outcomes collected by Australian National University for RWE
• Holds Health Canada Drug Establishment Licence authorising manufacture

Negative

• Shipment scale is limited: only 1,000 capsules supports ~300 sessions
• Continued access depends on import permits and local regulatory framework

Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that it has completed its first export of MDMA capsules to Australia in 2026 under the Authorised Prescriber Scheme.

The export included 1,000 of Optimi's MDMA capsules in a standardised 60 mg dosage form, supplied for use in authorised clinical programs for the treatment of Post-Traumatic Stress Disorder (PTSD). The export followed completion of Optimi's first 2026 production cycle, and receipt of the required Australian import permits and Health Canada export permits authorising international shipment.

Based on standard clinical protocols, this quantity of MDMA represents sufficient supply to support over 300 authorised PTSD treatment sessions under MDMA-assisted therapy programs.

Patient-Reported Outcomes (PROs) are being collected by the Australian National University (ANU), which is developing one of the most comprehensive real-world evidence (RWE) datasets to date on MDMA-assisted therapy for the treatment of Post-Traumatic Stress Disorder (PTSD).

Under the current framework, the Australian Department of Veterans' Affairs (DVA) offers reimbursement for eligible veterans receiving psychedelic-assisted therapy when delivered in accordance with program requirements.

According to the Australian Bureau of Statistics, approximately 5-6% of Australians experience PTSD in a given year, representing roughly 1.3 to 1.5 million people, with higher prevalence among veterans and first responders.

Optimi holds a Drug Establishment Licence issued by Health Canada that authorises the manufacture of the MDMA capsules for regulated therapeutic use, including the treatment of Post-Traumatic Stress Disorder (PTSD), where permitted by local authorities.

The Company's licensed Australian pharmacy partner acts as importer of record and national distributor, supplying authorised clinics across Australia in accordance with local regulatory requirements. This delivery enables participating clinics to proceed with MDMA-assisted therapy for eligible patients.

Clinicians, hospital networks, and authorised programs may seek information regarding access through Mind Medicine Australia at info@mindmedicineaustralia.org.

For global enquiries outside of Australia, please contact sales@optimihealth.ca.

For more information, please contact:
Dane Stevens, CEO
Optimi Health Corp.
(778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca

Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(262) 357-2918
OPTHF@mzgroup.us
www.mzgroup.us

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10615/283071_135cf3c014bb3a02_001full.jpg

About Optimi Health Corp.

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) is a leading producer of prescribed psychedelic treatments for mental health therapies. As a Health Canada-licensed, GMP compliant pharmaceutical manufacturer producing validated MDMA and botanical psilocybin products from two 10,000-square-foot facilities in British Columbia, Optimi supplies active pharmaceutical ingredients and finished dosage forms to regulated channels, with products currently in market for prescription use in Australia via the Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. For more information, please visit www.optimihealth.ca.

Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements"), including with respect to the role of psychedelic medicines in insured mental health care. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies, certain of which are unknown. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements. These statements may involve estimates, assumptions, and uncertainties that could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct, and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed in the Company's continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.ca. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283071

FAQ

What did Optimi Health (OPTHF) export to Australia on February 9, 2026?

Optimi exported 1,000 MDMA capsules (60 mg) to Australia for authorised clinical PTSD programs. According to the company, the shipment followed completion of its first 2026 production cycle and required Australian import and Health Canada export permits.

How many PTSD treatment sessions can OPTHF's February 2026 shipment support?

The shipment supports over 300 authorised PTSD treatment sessions under standard clinical protocols. According to the company, this estimate is based on typical dosing in MDMA-assisted therapy using the supplied 60 mg capsules.

Who is collecting patient-reported outcomes from OPTHF-supported MDMA therapy in Australia?

The Australian National University is collecting patient-reported outcomes (PROs) to build real-world evidence. According to the company, ANU is developing one of the most comprehensive RWE datasets on MDMA-assisted therapy for PTSD.

What regulatory authorisations enabled Optimi Health's MDMA export (OPTHF)?

The export was enabled by required Australian import permits and Health Canada export permits. According to the company, shipments were completed under the Authorised Prescriber Scheme and its Drug Establishment Licence authorises manufacture for regulated therapeutic use.

How can Australian clinics access information about OPTHF MDMA-assisted therapy supplies?

Clinicians and authorised programs may contact Mind Medicine Australia for access details and program requirements. According to the company, its licensed Australian pharmacy partner is the importer of record and national distributor for authorised clinics.